Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Lungs: What It Can (and Can’t) Do for Better Breathing
Transcript
- 0:00SPEAKER_00: Welcome to the Sorona Cell Podcast.
- 0:01SPEAKER_01: Thank you.
- 0:02SPEAKER_01: It's uh it's great to be here.
- 0:03SPEAKER_00: Yeah.
- 0:04SPEAKER_00: So today we are doing a deep dive into something I think a lot of you listening have probably wondered about, right?
- 0:09SPEAKER_01: Oh, absolutely.
- 0:11SPEAKER_01: The um the regenerative medicine space is notoriously loud.
- 0:16SPEAKER_01: There is just so much noise and frankly a lot of overpromising out there.
- 0:20SPEAKER_00: Yeah, exactly.
- 0:21SPEAKER_00: Which is why our mission for this deep dive is to look at the actual clinical protocols and you know the hard, verifiable research surrounding Sorona cell.
- 0:31SPEAKER_01: Right.
- 0:31SPEAKER_01: Grounding the discussion in real science.
- 0:34SPEAKER_00: Right.
- 0:34SPEAKER_00: We're specifically focusing on stem cell therapy for lungs today.
- 0:37SPEAKER_00: We want to unpack what this science can actually do, what it definitively cannot do, and just you know, cut through all that heavy medical jargon.
- 0:45SPEAKER_01: Aaron Powell It's so necessary because understanding how these cellular therapies operate in practice like in a real clinic is completely different from just reading theories online.
- 0:54SPEAKER_00: Aaron Powell Oh, 100%.
- 0:55SPEAKER_00: And speaking of the clinic, Sorona cell is actually based in Kuala Luncore, Malaysia.
- 0:59SPEAKER_01: Which is a massive hub for this kind of medical care right now.
- 1:02SPEAKER_00: Aaron Powell It really is.
- 1:03SPEAKER_00: I mean, they serve a huge local demographic, but they also get a major influx of international patients, particularly people flying in from Australia and the Middle East.
- 1:12SPEAKER_01: Aaron Powell Yeah, folks who are specifically seeking out um structured medically supervised care rather than just kind of rolling the dice on experimental medical tourism.
- 1:22SPEAKER_00: Aaron Powell Right, exactly.
- 1:24SPEAKER_00: And uh I found this really fascinating detail while looking into their background.
- 1:28SPEAKER_00: The name Cirona, it actually comes from a Celtic goddess.
- 1:33SPEAKER_01: Aaron Powell Oh, really?
- 1:33SPEAKER_01: I didn't know that.
- 1:34SPEAKER_00: Yeah.
- 1:34SPEAKER_00: A Celtic goddess of health and protection.
- 1:37SPEAKER_01: Aaron Ross Powell Wow, that's actually a highly intentional namesake when you think about it.
- 1:40SPEAKER_00: Aaron Ross Powell How so?
- 1:41SPEAKER_01: Aaron Ross Powell Well, if you analyze Cironacell's core clinical philosophy, that whole concept of protection is their guiding metric.
- 1:47SPEAKER_01: Trevor Burrus, Jr.
- 1:47SPEAKER_01: Oh, I see.
- 1:48SPEAKER_01: Yeah.
- 1:48SPEAKER_01: They focus so heavily on safe, structured, science-led care.
- 1:52SPEAKER_01: I mean, in this industry, you you unfortunately see clinics selling these like wild, exaggerated, quick fix miracles.
- 2:00SPEAKER_01: Oh, yeah.
- 2:00SPEAKER_00: Curals in a bottle.
- 2:01SPEAKER_01: Trevor Burrus, Jr.: Exactly.
- 2:02SPEAKER_01: And CeronaCell actively pushes against that narrative.
- 2:05SPEAKER_01: Their entire operational ethos is built around protecting the patient through rigorous medical standards, setting realistic expectations, and utilizing biology to actually defend the body.
- 2:18SPEAKER_00: Aaron Powell Okay, let's unpack this.
- 2:20SPEAKER_00: Because to truly understand why there is such a massive global interest in regenerative medicine for chronic lung conditions, we have to look under the hood at the mechanics.
- 2:28SPEAKER_00: Aaron Powell We do.
- 2:29SPEAKER_00: I mean, before we can even begin to understand how stem cells might support a compromised lung, we have to understand the microscopic destruction that happens in the first place, right?
- 2:38SPEAKER_01: Aaron Powell Yeah, absolutely.
- 2:39SPEAKER_01: Because the environment inside your lungs is just it's an incredibly intricate ecosystem.
- 2:43SPEAKER_00: Aaron Powell It's not just like a hollow balloon that inflates and deflates.
- 2:48SPEAKER_01: Aaron Powell No, not at all.
- 2:49SPEAKER_01: You have millions of these microscopic air sacs called alveoli.
- 2:54SPEAKER_00: Aaron Powell Right.
- 2:54SPEAKER_00: I've heard the analogy that if you took all those air sacs in a healthy pair of lungs and flatten them out, they'd cover the surface area of an entire tennis court.
- 3:02SPEAKER_01: That's spot on.
- 3:03SPEAKER_01: It's a massive surface area.
- 3:05SPEAKER_01: And within those delicate sacs, you have single, highly specialized cells.
- 3:09SPEAKER_00: Aaron Powell And their only job is basically grabbing oxygen.
- 3:12SPEAKER_01: Aaron Powell Exactly.
- 3:13SPEAKER_01: Their entire biological purpose is to grab oxygen molecules from the air and hand them over to your bloodstream.
- 3:20SPEAKER_01: And then standing guard right next to them, you have other cell types whose job is to protect the airways, sweep out microscopic debris, and you know maintain the flexible structural integrity of the lung tissue.
- 3:32SPEAKER_00: I always picture it like a highly synchronized factory floor.
- 3:35SPEAKER_00: Like every single cell has a specific station, a specific tool, and a very specific job to keep the assembly line moving.
- 3:42SPEAKER_01: Aaron Powell That is a perfect visualization.
- 3:44SPEAKER_01: But um over time, that factory floor can be subjected to immense compounding stress.
- 3:50SPEAKER_00: Like from smoking.
- 3:51SPEAKER_01: Yeah, decades of inhaling cigarette smoke or surviving severe respiratory infections like pneumonia.
- 3:57SPEAKER_00: Aaron Powell Or even environmental toxins, right?
- 3:59SPEAKER_01: Exactly.
- 3:59SPEAKER_01: Or even the body's own immune system malfunctioning and mistakenly attacking the lung tissue.
- 4:04SPEAKER_00: Oh wow.
- 4:05SPEAKER_01: Yeah.
- 4:05SPEAKER_01: So when that chemical and physical damage happens repeatedly, the delicate alveolar tissue becomes chronically inflamed.
- 4:12SPEAKER_00: And the immune system just overreacts.
- 4:14SPEAKER_01: Basically.
- 4:15SPEAKER_01: The immune system rushes in to fight off the perceived threat, but it doesn't know when to stop.
- 4:20SPEAKER_00: Aaron Powell So it's just a constant state of alarm.
- 4:22SPEAKER_01: Aaron Ross Powell Right.
- 4:22SPEAKER_01: And that chronic smoldering inflammation eventually leads to lasting damage and severe scarring.
- 4:28SPEAKER_00: Aaron Ross Powell And scarring in the lungs is vastly different from like a scrape on your knee that just scabs over and fades away, isn't it?
- 4:36SPEAKER_01: Oh, vastly different.
- 4:37SPEAKER_01: Scar tissue inside the lungs is rigid, it's thick, it's stiff, and it fundamentally lacks elasticity.
- 4:44SPEAKER_00: Which is terrifying when you think about it.
- 4:46SPEAKER_01: Aaron Powell Medically we call this pulmonary fibrosis.
- 4:49SPEAKER_01: As the tissue thickens and stiffens, those tiny air sacs are physically crushed.
- 4:54SPEAKER_00: Or completely blocked.
- 4:55SPEAKER_01: Yeah.
- 4:55SPEAKER_01: They can no longer transfer oxygen efficiently into the blood.
- 4:58SPEAKER_01: The architectural structure of the lung is permanently altered.
- 5:02SPEAKER_00: So using the analogy from earlier, the factory floor essentially gets paved over with concrete.
- 5:07SPEAKER_01: That's exactly what happens.
- 5:08SPEAKER_00: And the so what for you, the listener tuning into this, is that when pulmonary function drops to that level, everyday life just becomes a monumental, terrifying challenge.
- 5:17SPEAKER_01: It really does.
- 5:18SPEAKER_00: We're talking about basic survival tasks.
- 5:21SPEAKER_00: Making a cup of coffee, walking up a single flight of stairs, or, you know, even just carrying a light bag of groceries leaves a patient completely exhausted and gasping for air.
- 5:30SPEAKER_01: Aaron Powell And standard medical care for this level of disease usually involves daily bronchodilator inhalers to force the airways open and pulmonary rehabilitation and eventually heavy reliance on supplemental oxygen tanks.
- 5:45SPEAKER_00: Aaron Powell Which, I mean, those interventions are absolutely vital for survival, obviously.
- 5:48SPEAKER_01: Aaron Powell Yes, they keep people alive, but they are often palliative.
- 5:52SPEAKER_00: Meaning they just manage the symptoms.
- 5:54SPEAKER_01: Exactly.
- 5:54SPEAKER_01: They manage the decline, but they sometimes leave patients still struggling heavily to just manage their day-to-day lives.
- 6:00SPEAKER_00: Aaron Powell And what happens when those stop working?
- 6:02SPEAKER_01: Well, in the very late stages, the only standard medical option left is a full lung transplant.
- 6:07SPEAKER_00: Aaron Powell Right.
- 6:08SPEAKER_00: But getting a lung transplant isn't like getting a new set of tires.
- 6:11SPEAKER_00: It's an incredibly intense, brutal process.
- 6:14SPEAKER_01: Aaron Powell It is.
- 6:15SPEAKER_01: The wait lists are years long, the surgical risks are astronomically high, and the post-operative regimen requires a lifetime of immunosuppressant drugs.
- 6:24SPEAKER_00: So it's simply not a suitable or even available option for the vast majority of patients.
- 6:29SPEAKER_01: Not at all.
- 6:30SPEAKER_00: So if you're a patient staring down the barrel of a lifetime tethered to an oxygen tank, you're not going to just accept that.
- 6:36SPEAKER_00: You're going to look for a way to stop the scarring.
- 6:38SPEAKER_01: Right, which is exactly why the medical world started looking at stem cells.
- 6:42SPEAKER_01: Patients naturally seek out adjunct therapies to support their failing respiratory system.
- 6:47SPEAKER_01: Makes total sense.
- 6:48SPEAKER_01: But um we really have to address a major misconception right here.
- 6:52SPEAKER_00: Okay, let me guess.
- 6:53SPEAKER_00: If traditional medicines are like putting a band-aid on a declining engine, are stem cells actually building a new engine overnight?
- 7:01SPEAKER_01: That is the exact trap many patients fall into, and it is a misconception we need to firmly clear up.
- 7:06SPEAKER_00: So they don't build a new engine.
- 7:08SPEAKER_01: No.
- 7:08SPEAKER_01: The clinical reality is that stem cell therapy is an adjunct.
- 7:11SPEAKER_00: An adjunct.
- 7:12SPEAKER_01: Yes.
- 7:13SPEAKER_01: It is a supportive biological addition to a patient's wider treatment plan.
- 7:17SPEAKER_01: It is absolutely not a replacement for your pulmonologist, your standard medications, or your emergency inhalers.
- 7:24SPEAKER_00: So we aren't growing a shiny new set of lungs in a lab somewhere and swapping them out.
- 7:28SPEAKER_01: We are not.
- 7:29SPEAKER_01: It is not about building a new lung overnight.
- 7:32SPEAKER_00: Then what is it doing?
- 7:33SPEAKER_01: It is about altering the toxic environment of the existing damaged lung.
- 7:39SPEAKER_01: It's about utilizing biological mechanisms to support the body's natural healing conditions.
- 7:45SPEAKER_00: To calm down that chronic, smoldering inflammation paving over the factory floor.
- 7:50SPEAKER_01: Precisely.
- 7:50SPEAKER_01: And to fiercely protect the tissue that is still actively functioning.
- 7:54SPEAKER_00: Okay, so since we aren't building a brand new lung, what exactly are these specialized cells doing?
- 7:59SPEAKER_00: Let's dive into the specific science of the cells Cerona cell actually utilizes.
- 8:04SPEAKER_01: I think that's a great next step.
- 8:06SPEAKER_00: Because you know, we have to define our terms clearly.
- 8:08SPEAKER_00: The phrase stem cell covers a massive spectrum of biology.
- 8:12SPEAKER_00: And some of it carries some pretty controversial baggage from decades ago.
- 8:16SPEAKER_01: It does, but Cirona cell is explicitly clear on their cellular protocols.
- 8:20SPEAKER_01: They do not use embryonic stem cells.
- 8:23SPEAKER_00: Okay.
- 8:23SPEAKER_00: That's an important distinction.
- 8:24SPEAKER_01: Very.
- 8:25SPEAKER_01: They also do not use what are called experimental pluripotent stem cells in their clinical services.
- 8:30SPEAKER_00: Pluripotent, what does that mean exactly?
- 8:33SPEAKER_01: Pluripotent cells are cells that have the ability to turn into almost any tissue type in the body.
- 8:38SPEAKER_00: Which sounds kind of amazing, honestly.
- 8:40SPEAKER_00: Like a science fiction novel.
- 8:42SPEAKER_01: It sounds great in theory, yeah.
- 8:44SPEAKER_01: But in a real clinical setting, it is highly unpredictable and carries significant risks, including the potential for uncontrolled cellular growth.
- 8:52SPEAKER_00: Oh, like tumors.
- 8:53SPEAKER_01: Yeah, we don't want that.
- 8:54SPEAKER_00: Exactly.
- 8:55SPEAKER_00: Instead, Cyron uses what are called WJMSCs.
- 9:00SPEAKER_01: Okay, WJMSCs, let me break that acronym down for our listeners.
- 9:03SPEAKER_01: These are ethically sourced umbilical core-derived mesenchymal stem cells.
- 9:09SPEAKER_00: Right.
- 9:09SPEAKER_00: And the mesenchymal part is the key here.
- 9:11SPEAKER_00: Trevor Burrus, Jr.
- 9:11SPEAKER_01: Because unlike those pluripotent cells that try to become brand new tissue, mesenchymal cells act more like general contractors or site managers, right?
- 9:20SPEAKER_00: Aaron Powell That's a great way to put it.
- 9:21SPEAKER_00: They manage the repair process.
- 9:22SPEAKER_01: And these specific cells come exclusively from the Wharton's jelly inside the umbilical cords of healthy full-term deliveries, right?
- 9:29SPEAKER_01: Trevor Burrus, Jr.
- 9:29SPEAKER_00: Yes, gathered with full informed donor consent.
- 9:32SPEAKER_00: Which is literally just biological material that is normally discarded as medical waste after a healthy birth, anyway.
- 9:38SPEAKER_01: Exactly.
- 9:39SPEAKER_01: And the Wharton's jelly inside that umbilical cord is just incredibly rich in these young, highly active mesenchymal stem cells.
- 9:47SPEAKER_00: Aaron Powell Because they're brand new.
- 9:48SPEAKER_01: Right.
- 9:48SPEAKER_01: Because they are essentially brand new cells, they possess very potent immunomodulatory properties.
- 9:54SPEAKER_00: Immunomodulatory.
- 9:55SPEAKER_00: So they regulate the immune system.
- 9:57SPEAKER_01: Yes.
- 9:57SPEAKER_01: They are highly efficient at balancing and regulating immune responses.
- 10:01SPEAKER_01: But, you know, simply sourcing good cells is only half the battle.
- 10:05SPEAKER_01: It's the other half.
- 10:06SPEAKER_01: The other half, and this is where the regenerative medicine industry often falters, is strict laboratory quality control.
- 10:12SPEAKER_00: Aaron Powell Right.
- 10:13SPEAKER_00: Looking at Serono cells lab standards, they operate under VSL2 laboratory standards, utilizing CGMP and ISO 9001 certifications.
- 10:22SPEAKER_01: Which is a lot of acronyms.
- 10:23SPEAKER_00: Trevor Burrus It's total alphabet soup.
- 10:26SPEAKER_00: But it translates directly to patient safety.
- 10:28SPEAKER_00: I mean, BSL2 means biosafety level two.
- 10:30SPEAKER_01: Yes.
- 10:30SPEAKER_00: We're talking about restricted access laboratories, negative pressure environments, and sterile biological safety cabinets.
- 10:37SPEAKER_01: Ensuring that not a single speck of dust or bacteria ever touches your cellular batch.
- 10:42SPEAKER_00: Aaron Powell Right.
- 10:42SPEAKER_00: And CGMP stands for current good manufacturing practice.
- 10:48SPEAKER_00: What this ensures is that every single batch of these early passage WJMSCs is identical in quality.
- 10:55SPEAKER_01: They undergo rigorous checks before they ever reach a patient.
- 10:57SPEAKER_00: What are they checking for exactly?
- 10:59SPEAKER_01: The lab tests for exact cellular identity, strict sterility to guarantee there are no bacterial or viral contaminants.
- 11:06SPEAKER_00: Very important.
- 11:07SPEAKER_01: Extremely.
- 11:08SPEAKER_01: And crucially, cell viability.
- 11:10SPEAKER_01: You need millions of live active cells, not dead biological matter.
- 11:15SPEAKER_00: That makes sense.
- 11:16SPEAKER_01: I should also note that in some specific global research contexts, adult cells extracted from a patient's own bone marrow are also discussed.
- 11:23SPEAKER_00: Oh, really?
- 11:24SPEAKER_01: Yeah.
- 11:24SPEAKER_01: If a patient's specific case warrants looking at bone marrow derived cells, Syrena's doctors explain those options and their limitations clearly.
- 11:31SPEAKER_00: But the umbilical ones are the main focus.
- 11:33SPEAKER_01: Right.
- 11:33SPEAKER_01: The umbilical WJMSCs remain a primary focus for their robust immune balancing effects in lung tissue.
- 11:39SPEAKER_00: Okay, so we have these verified highly active MSCs.
- 11:43SPEAKER_00: A patient receives them usually through just a simple IV infusion into a vein in their arm.
- 11:49SPEAKER_00: Yeah, correct.
- 11:50SPEAKER_00: But how do they actually get to the lungs to do their job?
- 11:54SPEAKER_00: I was looking into the circulatory pathway, and it turns out an IV is the perfect delivery system for lungs because of something called the first pass effect.
- 12:02SPEAKER_01: Yes, the anatomy works perfectly in our favor here.
- 12:05SPEAKER_00: Right.
- 12:06SPEAKER_00: When fluid goes into your vein, it travels directly to the right side of your heart, and the very first place the heart punks that blood is straight into the pulmonary capillary bed.
- 12:15SPEAKER_01: The massive network of blood vessels in the lungs.
- 12:18SPEAKER_00: Right.
- 12:18SPEAKER_00: So they can pick up oxygen.
- 12:20SPEAKER_00: So the stem cells essentially get delivered directly to the doorstep of the lung damage.
- 12:24SPEAKER_01: Exactly.
- 12:24SPEAKER_01: The pulmonary vascular bed naturally traps a large percentage of these intravenously administered MSCs.
- 12:31SPEAKER_00: And then what do they do once they're trapped there?
- 12:32SPEAKER_01: Once they reach that pulmonary environment, they act as those biological site managers we talked about.
- 12:37SPEAKER_01: They interact directly with the patient's immune pathways.
- 12:40SPEAKER_00: To downregulate the inflammation.
- 12:42SPEAKER_01: Yeah.
- 12:42SPEAKER_01: Right.
- 12:42SPEAKER_01: To actively reduce the harmful chronic inflammation that's driving the lung disease in the first place.
- 12:48SPEAKER_01: Wow.
- 12:49SPEAKER_01: They release specific growth factors that support the health of the blood vessels in the lungs, essentially amplifying the body's own natural repair signals that have just been totally overwhelmed by the disease.
- 13:00SPEAKER_00: Okay, here's where it gets really interesting.
- 13:02SPEAKER_01: Yeah.
- 13:03SPEAKER_00: Because in reading through these clinical protocols, I came across a specific term exosomes.
- 13:10SPEAKER_01: Ah, yes.
- 13:11SPEAKER_01: Exosomes.
- 13:12SPEAKER_00: But the best way I can conceptualize exosomes is to think of them like microscopic text messages.
- 13:17SPEAKER_01: I like that.
- 13:18SPEAKER_00: Like if the stem cell is the smartphone, the exosome is the tiny data packet flying through the body, carrying a specific coded message that says, hey, stop the immune attack over here.
- 13:28SPEAKER_00: Or hey, stimulate blood vessel repair immediately.
- 13:32SPEAKER_01: It is a phenomenal way to visualize it.
- 13:34SPEAKER_01: Exosomes are literally messenger vesicles.
- 13:36SPEAKER_00: So they aren't the whole cell.
- 13:37SPEAKER_01: No, they are tiny extracellular packets released by the stem cells.
- 13:41SPEAKER_01: They don't contain the whole cell machinery or the nucleus.
- 13:44SPEAKER_00: They just have the message.
- 13:45SPEAKER_01: Exactly.
- 13:46SPEAKER_01: They just contain the instructions, specific proteins, lipids, and genetic material.
- 13:50SPEAKER_00: That's incredible.
- 13:50SPEAKER_01: And Cyrona cell actually offers targeted exosome therapy as an added value service.
- 13:55SPEAKER_00: Oh, they combine them.
- 13:56SPEAKER_01: Yes.
- 13:57SPEAKER_01: When you combine the live active stem cells with an infusion of these targeted exosome text messages, you can significantly strengthen the support of signals being broadcast to the damaged lung tissue.
- 14:09SPEAKER_00: I mean theory and lab mechanisms are fascinating, but we have to look at what happens when real human beings actually undergo these therapies.
- 14:17SPEAKER_01: Always.
- 14:17SPEAKER_01: We have to look at the data.
- 14:19SPEAKER_00: Right.
- 14:19SPEAKER_00: Let's move out of the Petri dish and look at the human-focused research.
- 14:22SPEAKER_01: Aaron Powell Well, we have some compelling clinical evidence to examine, starting with a pilot study conducted at Van Han General Hospital in Vietnam.
- 14:29SPEAKER_00: This trial focused on adults suffering from moderate to severe COPD, right?
- 14:34SPEAKER_00: Chronic obstructive pulmonary disease.
- 14:36SPEAKER_01: Yes.
- 14:37SPEAKER_01: These are patients whose daily lives were severely impacted by breathing difficulties.
- 14:42SPEAKER_00: Aaron Ross Powell And they received AV infusions of umbilical cord MSCs?
- 14:46SPEAKER_01: Correct.
- 14:47SPEAKER_01: And the researchers tracked their progress meticulously for six months.
- 14:51SPEAKER_00: And the standout takeaway from the data was the safety profile, wasn't it?
- 14:55SPEAKER_00: Across the board, they reported zero severe adverse events and absolutely no toxicities related to the infusion.
- 15:02SPEAKER_01: And in any early phase clinical trial, safety is always the primary endpoint.
- 15:07SPEAKER_01: You have to prove the intervention doesn't cause harm.
- 15:09SPEAKER_00: First, do no harm.
- 15:10SPEAKER_01: Exactly.
- 15:11SPEAKER_01: But they also observed significant clinical benefits.
- 15:15SPEAKER_01: The patients reported a measurable decrease in severe exacerbations.
- 15:19SPEAKER_00: And for a COPD patient, an exacerbation is terrifying.
- 15:22SPEAKER_01: It is.
- 15:22SPEAKER_01: It's a sudden flare-up where breathing becomes so difficult it often requires an emergency room visit and heavy steroids.
- 15:28SPEAKER_01: Right.
- 15:29SPEAKER_01: So reducing those events drastically changes a patient's psychological and physical state.
- 15:33SPEAKER_01: They also noted an overall improvement in the patient's self-reported quality of life scores.
- 15:38SPEAKER_00: Which is huge.
- 15:39SPEAKER_00: But um I didn't notice a very specific detail in that data that I want to push back on, though.
- 15:44SPEAKER_00: Oh, what's that?
- 15:45SPEAKER_00: Well, the study noted that objective lung function measures, specifically FEV1, which is a breathing test, measuring the sheer volume of air you can forcefully exhale in one second.
- 15:55SPEAKER_01: Yes, a very standard pulmonary test.
- 15:58SPEAKER_00: Trevor Burrus, Jr.
- 15:58SPEAKER_00: Right.
- 15:58SPEAKER_00: It didn't actually show strong, statistically significant improvements.
- 16:03SPEAKER_00: Wait, it says lung function measures like FEV1 didn't show strong changes.
- 16:07SPEAKER_00: So what does this all mean?
- 16:09SPEAKER_00: If lung capacity isn't drastically changing, why are patients feeling better?
- 16:13SPEAKER_01: Aaron Powell What's fascinating here is the critical distinction between curing architectural damage and managing the physiological environment.
- 16:21SPEAKER_00: Aaron Powell Okay, break that down for me.
- 16:22SPEAKER_01: Aaron Powell The physical scarring in the lungs, the rigid fibrotic tissue we talked about earlier, it has not vanished.
- 16:29SPEAKER_00: Aaron Powell The concrete is still on the factory floor.
- 16:32SPEAKER_01: Exactly.
- 16:32SPEAKER_01: The stem cells did not dissolve the scar tissue.
- 16:35SPEAKER_01: The FEV1 test reflects that structural limitation.
- 16:38SPEAKER_01: The lungs still cannot expand to its original youthful volume.
- 16:42SPEAKER_01: Aaron Powell Okay.
- 16:43SPEAKER_00: So why are they feeling better?
- 16:44SPEAKER_01: Because the stem cells are drastically reducing the systemic and localized inflammation.
- 16:49SPEAKER_01: The patient's body isn't constantly fighting itself anymore.
- 16:53SPEAKER_00: Uh, I see.
- 16:53SPEAKER_01: The airways are less irritated, less swollen, and produce less excess mucus.
- 16:58SPEAKER_00: Oh, so it's like turning off the deafening fire alarm in a building that had a fire.
- 17:01SPEAKER_01: Right.
- 17:01SPEAKER_00: The structural damage to the walls is still there, but at least the noise has stopped, the sprinklers are off, and you can finally think, function, and walk through the halls again.
- 17:10SPEAKER_01: A very apt comparison.
- 17:12SPEAKER_01: It proves that providing biological support, calming the hostile environment, and managing the cascading symptoms is a highly beneficial, realistic goal.
- 17:21SPEAKER_00: It radically improves the patient's day-to-day existence.
- 17:24SPEAKER_01: Even if a total cure of the lung structure isn't happening.
- 17:27SPEAKER_01: And we see similar supportive outcomes when we look at isolated case reports, though we must view them with appropriate scientific caution.
- 17:35SPEAKER_00: Right, like a highly detailed case report out of Sipping Hospital of China Medical University.
- 17:39SPEAKER_01: Yes, that's a notable one.
- 17:41SPEAKER_00: They documented the journey of a 56-year-old man suffering from severe idiopathic pulmonary fibrosis.
- 17:47SPEAKER_00: This patient was in a very critical state, actively requiring supplemental oxygen therapy just to maintain basic physiological function.
- 17:56SPEAKER_01: He was very sick.
- 17:57SPEAKER_00: And they administered a targeted 4V infusion of umbilical cord MSEs.
- 18:03SPEAKER_00: Over a structured 12-month follow-up period, his clinical breathing markers improved, his daily reliance on that supplemental oxygen tank was reduced.
- 18:12SPEAKER_01: Which is incredible for his quality of life.
- 18:15SPEAKER_00: And again, zero serious side effects were reported from the cellular infusion.
- 18:19SPEAKER_01: It is a deeply compelling narrative for that individual, but as researchers and clinicians, we must always add the necessary caveat here.
- 18:26SPEAKER_00: Right.
- 18:27SPEAKER_00: It's just one guy.
- 18:28SPEAKER_01: Exactly.
- 18:28SPEAKER_01: An N of 1, a single case report, is not a definitive cure, nor does it serve as a guarantee of identical results for the next patient who walks through the door.
- 18:37SPEAKER_01: What it does provide, however, are incredibly crucial safety signals.
- 18:41SPEAKER_01: It serves as a proof of concept that careful, targeted cellular protocols can offer tangible physiological support to people living with severe scarring conditions.
- 18:51SPEAKER_00: Buying them vital time.
- 18:52SPEAKER_01: Buying them time and quality of life while larger, broader, multi-center clinical trials continue to develop.
- 18:58SPEAKER_00: So knowing the underlying science, understanding the clinical data, and having a firm grasp on the realistic expectations.
- 19:06SPEAKER_00: How does a patient actually experience this?
- 19:08SPEAKER_01: Right.
- 19:09SPEAKER_01: The actual logistics.
- 19:10SPEAKER_00: Yeah.
- 19:11SPEAKER_00: If you are listening to this, analyzing your own lung scans, and considering reaching out to the clinic in Kualavumpur, what does the Syronacelle patient journey actually look like step by step?
- 19:22SPEAKER_01: Well, it is a highly structured, meticulously planned pathway.
- 19:25SPEAKER_01: It begins with the medical team itself.
- 19:27SPEAKER_00: Right.
- 19:28SPEAKER_00: It's not just one person.
- 19:29SPEAKER_01: No, this isn't just one rogue doctor operating out of a strip mall.
- 19:33SPEAKER_01: Saronacelle utilizes a comprehensive multidisciplinary team.
- 19:37SPEAKER_00: They have a whole roster of specialists.
- 19:39SPEAKER_01: Yes, you have experienced physicians from internal medicine, neurology, rehabilitation, and sports medicine, all collaborating on patient cases.
- 19:47SPEAKER_00: And they operate on three non-negotiable commitments, from what I read.
- 19:51SPEAKER_00: Clinical depth, transparent advice, and compassionate care.
- 19:55SPEAKER_01: That's right.
- 19:55SPEAKER_00: And to give you an idea of that clinical depth, they aren't uniquely treating lungs.
- 20:00SPEAKER_00: They design highly structured, supportive stem cell programs for severe neurological and brain conditions, complex autoimmune and inflammatory disorders.
- 20:10SPEAKER_01: Degenerative joint and spine issues, metabolic conditions.
- 20:13SPEAKER_00: Even science-based cellular anti-aging protocols.
- 20:17SPEAKER_01: Exactly.
- 20:18SPEAKER_01: But regardless of the specific condition being treated, the clinical pathway remains strictly standardized across four clear steps.
- 20:25SPEAKER_00: Aaron Powell Okay, let's walk through them.
- 20:27SPEAKER_00: Step one is the comprehensive medical evaluation.
- 20:30SPEAKER_01: Yes.
- 20:30SPEAKER_01: This is where you hand over your recent pulmonology reports, your high-resolution CT lung scans, and your recent breathing tests.
- 20:38SPEAKER_00: And this is where that commitment to transparent advice is truly tested.
- 20:42SPEAKER_01: Absolutely.
- 20:42SPEAKER_01: The doctors review everything to see if your biological environment can actually utilize the cells.
- 20:47SPEAKER_01: They practice strict honesty.
- 20:49SPEAKER_00: So they turn people away.
- 20:50SPEAKER_01: If they look at your scans and determine your lungs are too heavily scarred, or if you have an active untreated infection, they will look you in the eye and tell you that you will not benefit from this therapy.
- 21:00SPEAKER_01: They will simply not take you on as a patient just to charge you for a procedure.
- 21:04SPEAKER_00: That firm ethical boundary is what builds real, lasting medical trust.
- 21:09SPEAKER_01: It's essential.
- 21:10SPEAKER_01: Now, if you are accepted as a viable candidate, you move to step two, stem cell preparation.
- 21:16SPEAKER_00: This goes right back to the BSL II lab standards we broke down earlier.
- 21:20SPEAKER_01: Yes.
- 21:20SPEAKER_01: While the patient is preparing for their visit, the laboratory is conducting those strict identity, purity, and viability tests on the specific customized batch of cells being released for that exact patient.
- 21:32SPEAKER_00: Then comes step three, administration.
- 21:35SPEAKER_00: And I think a lot of people picture intense, painful surgery when they hear the phrase regenerative medicine.
- 21:41SPEAKER_01: Oh, they picture open chest surgery.
- 21:43SPEAKER_00: Right.
- 21:43SPEAKER_00: But for lung protocols, it is entirely minimally invasive.
- 21:47SPEAKER_00: The WGMSEs are typically delivered slowly through a standard IV drip into a vein in your arm.
- 21:53SPEAKER_01: It's very straightforward.
- 21:54SPEAKER_00: You are literally just resting in a comfortable treatment chair, reading a book, or watching a show.
- 21:58SPEAKER_00: There's no heavy anesthesia.
- 22:00SPEAKER_00: No intubation, and certainly no open chest surgery involved here.
- 22:03SPEAKER_01: Aaron Powell, which is an absolute necessity for these patients.
- 22:06SPEAKER_00: Oh, because of their lungs.
- 22:07SPEAKER_01: Right.
- 22:08SPEAKER_01: Someone whose respiratory system is already severely compromised by COPD or fibrosis could not easily survive heavy general anesthesia and invasive chest surgery anyway.
- 22:18SPEAKER_00: That makes total sense.
- 22:19SPEAKER_01: The minimally invasive nature is what makes the adjunct therapy possible in the first place.
- 22:24SPEAKER_01: And finally, step four is the monitoring and follow-up.
- 22:29SPEAKER_00: Because the care doesn't just stop the second the IV is removed from your arm.
- 22:34SPEAKER_01: Oh, not at all.
- 22:34SPEAKER_01: The clinical team tracks your breathing symptoms, your daily energy levels, and your pulmonary function over time.
- 22:41SPEAKER_00: They adjust lifestyle and nutritional advice, right?
- 22:43SPEAKER_01: Exactly.
- 22:44SPEAKER_01: To ensure the cellular therapy integrates seamlessly with your overall pulmonary rehab back home.
- 22:49SPEAKER_00: If we connect this to the bigger picture, what Saronacell is doing is building a long-term medical relationship.
- 22:56SPEAKER_01: If we connect this to the bigger picture, yes, exactly.
- 22:59SPEAKER_01: They actively coordinate with your existing lung specialists and primary care doctors.
- 23:04SPEAKER_00: They aren't trying to replace them.
- 23:05SPEAKER_01: No.
- 23:06SPEAKER_01: They are tracking long-term clinical outcomes, watching for any side effects, and monitoring your overall progress, entirely avoiding the dangerous hype of a one-time miracle procedure.
- 23:17SPEAKER_00: Right.
- 23:17SPEAKER_00: So it is regenerative medicine positioned properly within the medical landscape.
- 23:23SPEAKER_01: As a sophisticated, integrated biological tool within a much broader comprehensive care plan.
- 23:29SPEAKER_00: Okay.
- 23:29SPEAKER_00: To summarize everything we've unpacked today for you listening at home.
- 23:32SPEAKER_01: Yeah.
- 23:33SPEAKER_00: When we talk about stem cell therapy for lungs, specifically through the clinical lens of Ceirona cell in Malaysia, we are talking about a carefully monitored, scientifically structured pathway.
- 23:43SPEAKER_01: A pathway for supportive care.
- 23:45SPEAKER_00: Yes.
- 23:45SPEAKER_00: It utilizes ethically sourced WJMSCs backed by rigorous BSL2 lab standards to provide deeply necessary supportive care directly to the pulmonary system.
- 23:55SPEAKER_01: It is not about growing a brand new lung.
- 23:57SPEAKER_00: No.
- 23:57SPEAKER_00: It is about aggressively reducing chronic inflammation, protecting the existing tissue, and fighting for a much better daily quality of life, all rooted in strict patient safety.
- 24:06SPEAKER_01: It really represents a fundamental shift in how we view internal healing.
- 24:10SPEAKER_00: It does.
- 24:11SPEAKER_01: And um leaves me with a thought I'd love for our listeners to deeply ponder before we go.
- 24:16SPEAKER_00: Oh, please, go ahead.
- 24:17SPEAKER_01: We talk earlier about exosomes acting as microscopic cellular text messages.
- 24:22SPEAKER_00: Right, telling the immune system what to do.
- 24:24SPEAKER_01: Well, if the future of treating chronic degenerative disease isn't about surgically cutting out the damage, but instead learning to speak the microscopic language of our own cells, coding a message to tell the immune system to stop attacking and start repairing.
- 24:39SPEAKER_00: Yeah.
- 24:39SPEAKER_01: What other incurable conditions are just waiting for the right cellular text message to arrive?
- 24:45SPEAKER_00: Wow.
- 24:46SPEAKER_00: That is an incredible, profound thought to end on.
- 24:49SPEAKER_00: Imagine finally cracking the code to that biological language.
- 24:53SPEAKER_01: It changes everything.
- 24:54SPEAKER_00: It really does.
- 24:55SPEAKER_00: Thank you so much for joining us on this deep dive.
- 24:58SPEAKER_00: And for everyone listening, stay curious, keep asking the hard questions.
- 25:01SPEAKER_00: And remember sometimes the most profound medical advancements don't look like building a brand new factory floor.
- 25:08SPEAKER_00: Sometimes they just look like bringing in the right biological managers to help the old machinery catch its breath again.
- 25:13SPEAKER_00: Catch you next time.